Iovance Biotherapeutics, Inc.
General ticker "IOVA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Iovance Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 0.3%.
Estimated limits based on current volatility of 8.8%: low 4.09$, high 4.75$
Factors to consider:
- Total employees count: 838 (+50.4%) as of 2024
- US accounted for 98.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Need for additional capital, Operating losses, Manufacturing risks, Pandemic risks, Economic downturns and volatility
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.79$, 5.15$]
- 2026-12-31 to 2027-12-31 estimated range: [2.11$, 5.73$]
Financial Metrics affecting the IOVA estimates:
- Positive: with PPE of -2.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -31.26 <= 0.01
- Positive: Investing cash flow per share per price, % of 4.91 > -0.63
- Positive: Shareholder equity ratio, % of 76.50 > 64.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term IOVA quotes
Long-term IOVA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.19MM | $164.07MM | $263.50MM |
| Operating Expenses | $461.75MM | $559.35MM | $666.86MM |
| Operating Income | $-460.56MM | $-395.28MM | $-403.36MM |
| Non-Operating Income | $13.04MM | $20.27MM | $10.31MM |
| R&D Expense | $344.08MM | $282.34MM | $300.27MM |
| Income(Loss) | $-447.52MM | $-375.00MM | $-393.05MM |
| Taxes | $-3.48MM | $-2.83MM | $-2.07MM |
| Profit(Loss)* | $-444.04MM | $-372.18MM | $-390.98MM |
| Stockholders Equity | $584.61MM | $710.40MM | $698.58MM |
| Inventory | $10.37MM | $51.52MM | $51.68MM |
| Assets | $780.35MM | $910.43MM | $913.17MM |
| Operating Cash Flow | $-361.82MM | $-352.98MM | $-302.41MM |
| Capital expenditure | $22.29MM | $11.07MM | $33.84MM |
| Investing Cash Flow | $-155.24MM | $-96.41MM | $47.50MM |
| Financing Cash Flow | $462.96MM | $390.66MM | $300.77MM |
| Earnings Per Share** | $-1.89 | $-1.28 | $-1.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.